Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$42.25+0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HRMY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On August 4, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On July 16, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary net product revenue for the second quarter of 2026. In addition, the Company reaffirmed its guidance related to 2026 net product revenue. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Chief Financial Officer — Glenn Reicin: Glenn Reicin resigned as Chief Financial Officer to pursue other career opportunities.
Results of Operations and Financial Condition. On May 7, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Chief Financial Officer — Sandip Kapadia: Mr. Kapadia is stepping down as CFO to pursue other career opportunities, and Glenn Reicin has been appointed as the new CFO.
Chief Operating Officer (COO) — Peter Anastasiou: Peter Anastasiou was promoted to COO and resigned from the board of directors.
Results of Operations and Financial Condition. On February 24, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On January 12, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2025. In addition, the Company provided guidance related to 2026 net product revenue and provided an update on clinical programs. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herei…
Results of Operations and Financial Condition. On November 4, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference .
Results of Operations and Financial Condition. On October 23, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary net product revenue for the third quarter of 2025. In addition, the Company provided updated guidance related to 2025 net product revenue. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference . Note Regarding Forward-Looking Statements Certain state…
Results of Operations and Financial Condition. On August 5, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Other Events. On June 5, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing a settlement agreement with Lupin Limited (“Lupin”), resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will be dismissed, and Lupin will receive a license to launch its g…
Results of Operations and Financial Condition. On May 6, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Director — Ron Philip: The filing discloses the appointment of a new independent director to fill a previously announced vacancy, which is a routine board composition change rather than a loss of a senior executive.
Chief Commercial Officer — Jeffrey Dierks: The Chief Commercial Officer is departing for personal reasons with a standard separation agreement, representing a genuine executive departure but not a forced termination or crisis.
Results of Operations and Financial Condition. On February 25, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On January 13, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2024. In addition, the Company provided guidance related to 2025 net product revenue and provided an update on clinical programs. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herei…
Results of Operations and Financial Condition. On October 29, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On August 6, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Director — Jack Bech Nielsen: A director resigned immediately due to health reasons, which is a genuine departure but typically less material than an executive officer departure.
Chief Medical & Scientific Officer — Kumar Budur: The filing discloses the internal promotion of the Chief Medical Officer to Executive Vice President and Chief Medical & Scientific Officer, accompanied by a salary increase and equity grants.
Results of Operations and Financial Condition. On April 30, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Entry into a Material Definitive Agreement. The information under the heading “LCA Amendments” under
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.